COMy 2023 | Novel technologies and the prognostic value of identifying subclones in myeloma

Jill Corre, PharmD, PhD, The Cancer University Institute of Toulouse Oncopole (IUCT), Toulouse, France, discusses methods to identify subclones in patients with multiple myeloma. Dr Corre first highlights liquid biopsy, which yields circulating tumor DNA (ctDNA) and can provide information on abnormalities across all subclones. Dr Corre also discusses single-cell analysis, which may provide more detailed information than bone marrow analysis and identify high-risk subclones that would be otherwise undetectable in a bone marrow sample. Dr Corre explains that this high-risk subclone identification may have a strong prognostic impact from diagnosis and could become a future diagnostic focus to prevent disease progression. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.